UOC
SPRO icon

UBS O'Connor’s Spero Therapeutics SPRO Stock Holding History

UBS O'Connor’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-51,400
Closed -$658K – 291
2019
Q1 		$658K Sell
51,400
-116,618
-69% -$1.24M 0.02% 192
2018
Q4 		$1.03M Sell
168,018
-1,982
-1% -$16.1K 0.04% 164
2018
Q3 		$1.79M Buy
+170,000
New +$1.97M 0.04% 176

Other funds holding SPRO

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

UBS O'Connor's SPRO Position: Q2 2019 in Review

UBS O'Connor sold out of Spero Therapeutics (SPRO) in Q2 2019, closing a stake of 51,400 shares — an estimated $658K sold.

UBS O'Connor first reported a position in SPRO in Q3 2018 and held it in 3 quarters. The position peaked at $1.79M in Q3 2018. 61 funds tracked by Wall St. Rank hold SPRO as of Q2 2019.

  • UBS O'Connor reported no remaining Spero Therapeutics position as of Q2 2019 after selling out during the quarter.
  • UBS O'Connor sold 51,400 Spero Therapeutics shares in Q2 2019, an estimated $658K.
  • UBS O'Connor first reported a position in Spero Therapeutics in Q3 2018 and held it in 3 quarters.
  • UBS O'Connor's Spero Therapeutics position peaked at $1.79M in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2019.

Based on UBS O'Connor's 13F filing for Q2 2019, filed 14 Aug 2019.